Cellarity is a technology company.
Cellarity has raised $240.0M across 2 funding rounds.
Key people at Cellarity.
Cellarity has raised $240.0M in total across 2 funding rounds.
Key people at Cellarity.
Cellarity has raised $240.0M in total across 2 funding rounds.
Cellarity's investors include Flagship Pioneering, Flagship Ventures.
Cellarity is a biotechnology company developing therapeutics by analyzing and altering cell behaviors using a platform that integrates single-cell technologies, multi-omics data, and machine learning.[1][2][3][5] It targets complex diseases by digitizing cellular behaviors, mapping network dynamics, and generating medicines that correct dysfunctional cell states, serving pharmaceutical researchers and patients with conditions driven by cellular cascades.[1][4][5] The platform, including the Cellarium digital twin and Cellarity Maps, has validated hypotheses in animal models and is advancing multiple programs toward clinical trials, promising faster drug discovery with higher success rates.[1][4]
Founded in 2017 within Flagship Labs—Flagship Pioneering's innovation foundry—Cellarity emerged from the life sciences venture firm's hypothesis-driven approach to re-architect therapeutic discovery.[1][2][4] Flagship Pioneering, backed by over $3.3 billion in commitments at launch, created Cellarity as the first company to target medicines at cell behaviors rather than single proteins or pathways.[2][4] The idea stemmed from recognizing that diseases involve dynamic cellular networks best understood through modern single-cell tools and AI, with early development yielding a broad platform demonstrated in preclinical models.[1][2]
Cellarity rides the convergence of AI-driven drug discovery and single-cell omics, trends exploding as diseases prove too complex for target-centric models.[1][3][5] Timing aligns with advances in multi-omics data and computational biology, enabling scalable mapping of cellular cascades amid rising failures in traditional pipelines (e.g., low Phase II success rates).[2][5] Market forces like surging biotech funding for AI platforms and demand for precision medicines in oncology, immunology, and neurodegeneration favor it, as seen in peers like Envisagenics.[3] By influencing ecosystem tools like Cellarity Maps, it democratizes cell biology insights, pushing pharma toward behavior-based paradigms.[1][4]
Cellarity is poised to advance clinical candidates from its pipeline, leveraging platform validations to secure partnerships or funding in a maturing AI-biotech market.[1][4] Trends like expanded multi-omics datasets and regulatory nods for AI-derived drugs will accelerate its trajectory, potentially yielding first approvals in cell-state therapies.[3][5] Its influence may grow by licensing maps or tech to big pharma, redefining discovery and tying back to its core mission of quantum leaps in therapeutic success.[1][2]
Cellarity has raised $240.0M across 2 funding rounds. Most recently, it raised $120.0M Series C in October 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2022 | $120.0M Series C | Flagship Pioneering, Flagship Ventures | |
| Feb 1, 2021 | $120.0M Series B | Flagship Pioneering, Flagship Ventures |
